A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1

Krebs, M.Brunsvig, P.Helland, A.Vinolas, N.Aix, S.Carcereny, E.Domine Gomez, M.Trigo Perez, J. M.Arriola, E.Garcia Campelo, R.Spicer, J.Thompson, J.Ortega Granados, A. L.Holt, R.Smethurst, D.Lorens, J.Shoaib, M.Siddiqui, A.Schoelermann, J.Lorens, K.Schmidt, E.Chisamore, M. J.Felip, E.2025-01-072025-01-072019-10-011556-0864https://hdl.handle.net/10668/26624enbemcentinibAXLPembrolizumabA Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1conference outputopen access10.1016/j.jtho.2019.08.7871556-1380http://www.jto.org/article/S1556086419314704/pdf492162202116